Compare Moderna, Inc. (MRNA) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs WD 40 Company — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while WD 40 Company trades at $202.29 (market cap $2.73B). The key difference: Moderna, Inc. is far larger — about 28.8× WD 40 Company's market cap, and WD 40 Company pays a 2% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and WD 40 Company for 22 Days on average.
| MRNA | WDFC | |
|---|---|---|
Market Cap | $78.65B | $2.73B |
Volume | 37,373,437 | 130,665 |
Sector | Health | Basic Materials |
52-Week High | $203.46 | $264.91 |
52-Week Low | $22.36 | $187.52 |
Typical Hold Time | 59 Days | 22 Days |
Enterprise Value | $74.80B | $2.79B |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
WDFC trades at $202.29, showing modest daily gains. The technical outlook is bullish, supported by moving averages, while recent earnings have largely beaten expectations. The company maintains strong profitability with a 13.22% net income margin and a 33.22% ROE, though valuation multiples like a P/E of 30.96 appear elevated. Positive news highlights strategic growth initiatives and institutional buying interest.
The stock presents a mixed outlook; robust fundamentals and growth strategy support upside, but high valuation and margin pressures from input costs pose risks. Analyst consensus is cautious with a majority hold rating, indicating balanced but not aggressive investor sentiment near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
